	US 12,440,556 B2
	Genetically modified cell line for production of Marek's disease virus vaccine and methods of making and using the same
Keith Allen Ameiss, Kalamazoo, MI (US); and Everett Lee Rosey, Schoolcraft, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Filed by Zoetis Services LLC, Parsippany, NJ (US)
Filed on Jun. 14, 2021, as Appl. No. 17/347,075.
Claims priority of provisional application 63/039,021, filed on Jun. 15, 2020.
Prior Publication US 2021/0386854 A1, Dec. 16, 2021
Int. Cl. C12N 5/071 (2010.01); A61K 39/255 (2006.01); C12N 5/10 (2006.01); C12N 7/00 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01)

CPC A61K 39/255 (2013.01) [C12N 5/0602 (2013.01); C12N 5/10 (2013.01); C12N 7/00 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 2310/20 (2017.05); C12N 2710/16034 (2013.01)]

23 Claims

1. A genetically modified avian cell line capable of supporting high-titer growth of a Marek's Disease Virus (MDV), wherein the genetic modification comprises a genetic alteration of one or more of the following genes: SLAMF8, HTR2A, STAT4, CTSL2, and COBLL1; and wherein high-titer growth refers to at least a 2-fold higher yield in the viral titer as that achieved with the same MDV strain in a parent avian cell line.